Nomura Asset Management’s Denali Therapeutics DNLI Stock Holding History

Nomura Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$945K	Hold	36,732	–	–	﹤0.01%	754
2026 Q1	$705K	Buy	+36,732	New	+$731K	﹤0.01%	789
2024 Q4	–	Sell	-65,033	Closed	-$1.66M	–	1497
2024 Q3	$1.89M	Buy	+65,033	New	+$1.61M	0.01%	738
2022 Q1	–	Sell	-10,402	Closed	-$358K	–	1557
2021 Q4	$464K	Buy	+10,402	New	+$493K	﹤0.01%	910
2021 Q3	–	Sell	-7,210	Closed	-$406K	–	989
2021 Q2	$566K	Hold	7,210	–	–	﹤0.01%	903
2021 Q1	$412K	Buy	+7,210	New	+$483K	﹤0.01%	903

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nomura Asset Management's DNLI Position: Q2 2026 in Review

Nomura Asset Management held its Denali Therapeutics (DNLI) position steady in Q2 2026 at 36,732 shares worth $945K. The position accounts for ﹤0.01% of the portfolio, ranked #754.

Nomura Asset Management first reported a position in DNLI in Q1 2021 and has held it in 6 quarters since. The position peaked at $1.89M in Q3 2024. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Nomura Asset Management held 36,732 shares of Denali Therapeutics worth $945K as of Q2 2026.
Nomura Asset Management left its Denali Therapeutics share count unchanged in Q2 2026.
Denali Therapeutics made up ﹤0.01% of Nomura Asset Management's portfolio in Q2 2026, its #754 holding.
Nomura Asset Management first reported a position in Denali Therapeutics in Q1 2021 and has held it in 6 quarters since.
Nomura Asset Management's Denali Therapeutics position peaked at $1.89M in Q3 2024.
292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Nomura Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.